Business context and reporting period
Globe Life Inc. filed this unaudited Form 10-Q for the three months ended March 31, 2024, comparing results with Q1 2023. The insurer primarily sells individual life and supplemental health insurance in the United States through exclusive and independent agencies and direct-to-consumer channels.
Unless otherwise noted, financial amounts below are in millions of dollars. The filing reports financial statements in thousands.
Financial results and position
| Metric | Q1 2024 / March 31, 2024 | Prior period / comparison |
|---|---|---|
| Total revenue | $1,416.1 | $1,321.3; up 7% |
| Total premiums | $1,145.3 | $1,095.1; up 5% |
| Net investment income | $282.6 | $257.1; up 10% |
| Net income | $254.2; diluted EPS $2.67 | $223.6; diluted EPS $2.28 |
| Net operating income (non-GAAP) | $264.1; diluted per-share amount $2.78 | $248.0; diluted per-share amount $2.53 |
| Operating cash flow | $350.8 | $477.3 |
| Total assets / shareholders’ equity | $28,570.6 / $5,039.2 | At Dec. 31, 2023: $28,051.5 / $4,486.8 |
| Cash and short-term investments | $141.96 | $184.90 at Dec. 31, 2023 |
| Total debt, book value | $2,363.5 | $2,115.7 at Dec. 31, 2023 |
- Life premium was $804.3 million, up 4%; health premium was $341.0 million, up 6%. Life underwriting margin was $309.0 million, or 38% of premium, versus $291.3 million and 38%. Health underwriting margin was $93.8 million, or 27% of premium, versus $91.3 million and 28%.
- Excess investment income, a non-GAAP segment measure, rose 50% to $43.8 million, reflecting growth in invested assets and higher yields. The effective annual yield on the fixed-maturity portfolio was 5.24%, compared with 5.18% a year earlier.
- Insurance administrative expenses rose 9% to $80.4 million and increased to 7.0% of premium from 6.7%, with higher technology, legal, and salary costs.
- Available-for-sale fixed maturities had a fair value of $18.1 billion. Their net unrealized loss widened to approximately $1.4 billion from $1.0 billion at year-end, which management attributed primarily to higher market rates. The portfolio’s average composite rating was A-; 97% was investment grade.
- Accumulated other comprehensive loss improved by $305.2 million during the quarter to $2.47 billion, mainly reflecting the change in the discount rate for future policy benefits, partly offset by investment losses.
Material changes versus Q1 2023
- Net income increased 14% and diluted EPS increased 17%. Net operating income increased 6%; its growth was led by a 50% rise in excess investment income and a 6% rise in life underwriting margin.
- Reported net income also benefited from less-negative realized losses: realized losses, net of tax, were $9.3 million versus $24.4 million. In Q1 2024, fair-value changes on investments accounted for a significant portion of investment losses; these items are excluded from management’s non-GAAP operating measure.
- Total net sales increased 7% to $204 million, and first-year collected premium rose 10% to $161 million. Average producing agent count across exclusive agencies increased 13%. Life net sales rose 7%; health net sales rose 9%.
- Operating cash flow declined by $126.5 million year over year; management attributed the reduction primarily to timing fluctuations in settlement of certain amounts in other liabilities. Investing cash outflow increased as investment acquisitions rose.
- Debt increased, including $242 million of short-term FHLB borrowings at quarter-end, compared with none at year-end. Long-term debt remained approximately $1.63 billion. Financing costs increased 15%, primarily due to higher short-term interest rates.
Outlook, commentary, risks and unusual items
- The filing provides no specific full-year earnings or EPS guidance. Management projects 2024 subsidiary dividends of $490–$510 million and excess cash flows of $450–$470 million. It expects liquidity to be sufficient for operations and targeted capital levels through available liquid assets, internally generated cash flow, and credit facilities.
- Globe Life targets a consolidated Company Action Level risk-based capital ratio of 300%–320% for 2024; its reported 2023 ratio was 314%. Management says it considers the target adequate for the company’s ratings and risk profile.
- The revolving credit facility was amended to mature in 2029, with capacity of $1 billion and a possible increase to $1.25 billion. At March 31, $561 million remained available; the company reported compliance with covenants. The company declared a quarterly dividend of $0.24 per share, paid May 1, 2024. On April 25, the board authorized up to $1.3 billion of repurchases through December 31, 2025.
- Management said Q1 repurchases were lower than anticipated because repurchases were paused while the company evaluated a potential acquisition; Globe Life ultimately did not pursue it. It repurchased 128,000 shares for $15.6 million from parent-company excess cash flow during the quarter.
- Management reported favorable reserve remeasurement gains totaling $8.1 million, compared with a $0.7 million gain in Q1 2023. These reflected favorable actual experience relative to assumptions in both life and health. The filing says there were no changes to the judgments, assumptions, or methods used to measure future policy benefits.
- Legal and reputational matters warrant attention. Globe Life and American Income received U.S. Attorney’s Office subpoenas seeking information about sales practices of certain independent agents; the company said it was cooperating, that no claims had been asserted, and that it did not then believe a material loss was reasonably possible or probable. Short-seller reports in April 2024 prompted negative publicity and a significant stock-price decline. A securities class action was filed April 30, 2024, after quarter-end, alleging misleading disclosures; the company intends to defend it, and potential loss could not be estimated. The filing also notes agent-classification and other litigation; management generally did not expect the disclosed litigation to have a material effect, while acknowledging outcome uncertainty.
- Other investment and liquidity exposures include $686 million of unfunded investment-fund commitments, one delinquent commercial mortgage loan and one loan in non-accrual status at March 31, 2024, and $1.4 billion fair value of assets pledged for FHLB advances and reinsurance.
- Disclosed risks include insurance regulation and rate approvals, agent or third-party misconduct, reputational harm, litigation and regulatory scrutiny, interest-rate and credit-market movements, economic conditions, and the ability to access short-term and debt markets. Management said disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Review the full disclosures and subsequent developments concerning the DOJ subpoenas, April short-seller allegations, and securities class action; the filing’s loss assessment is based on information available at the time.
- Track sales, agent recruitment and productivity, especially the DTC decline in life net sales and the health segment’s margin decrease, alongside the reported overall premium and net-sales growth.
- Monitor investment portfolio credit quality, unrealized losses, commercial mortgage loan performance, and the liquidity and timing terms of investment-fund commitments.
- Assess debt and liquidity trends, including FHLB and commercial-paper borrowings, available credit capacity, cash flows, and the targeted statutory capital ratio.
- Reconcile GAAP net income with management’s non-GAAP net operating income and distinguish recurring insurance performance from realized investment results and reserve remeasurement effects.